OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Psychopharmacology is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness	39
History repeating: guidelines to address common problems in psychedelic science	28
Risperidone-induced neuroleptic malignant syndrome: a case report	26
Tardive dyskinesia: understanding current challenges in diagnosis and treatment	24
Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study	24
Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report	23
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital	20
Metformin co-commencement at time of antipsychotic initiation for attenuation of weight gain: a systematic review and meta-analysis	20
Drug safety in older patients with alcohol use disorder: a retrospective cohort study	20
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation	18
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation	16
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand	16
Will psilocybin lose its magic in the clinical setting?	14
Analysis of the clinical characteristics of olanzapine-induced acute pancreatitis	12
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications	12
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults	12
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics	12
Neuroimaging features of cognitive impairments in schizophrenia and major depressive disorder	11
Risperidone ISM^®: review and update of its usefulness in all phases of schizophrenia	10
Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study	10
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial	8
Sublingual asenapine for agitation in malabsorptive states: three patient cases	8
Pathophysiology, prognosis and treatment of tardive dyskinesia	8
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area	8
The cardiovascular safety of tricyclic antidepressants in overdose and in clinical use	8

Comment on: History repeating: guidelines to address common problems in psychedelic science	8
Low-frequency repetitive transcranial magnetic stimulation for the treatment of post-traumatic stress disorder and its comparison with high-frequency stimulation: a systematic review and meta-analysis	6
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action	6
Corrigendum to ‘Comment on: History repeating: guidelines to address common problems in psychedelic science’	6
Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review	6
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia	6